Registry data provides stable disease course and ambulation as preferred endpoint in Vanishing White MatterRegistry Data Helps Plan Trials for Vanishing White Matter

medRxiv Published August 23, 2026 Study authors: van Voorst, R. J.; Gonzato, E.; Hamilton, E. M. C.; Stellingwerf, M. D.; Postema, M. C.; Berkhof, J.… DOI ↗ Editorial oversight: Dr. Ji-eun Park, MD · Brain, Mind & Pain

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Note that registry data for Vanishing White Matter shows no disease drift since 1991 and supports ambulation as a trial endpoint.

This case study analyzed registry data from 462 patients with vanishing white matter (VWM) to evaluate the feasibility of using historical controls in clinical trial design. The analysis focused on methodological considerations including patient selection, disease drift, and endpoint selection for this ultra-rare condition.

Key findings indicated no evidence of drift in the disease course from 1991 onwards. Regarding endpoints, ambulation was identified as a more preferable outcome than survival. Analysis of HUI multiscores showed a distinct ordering, reflecting an association between multi-domain function and disease progression. Additionally, while females initially appeared to have milder disease and later onset, this sex effect was eliminated when adjusted for age of onset.

A primary limitation noted is that rapid decline episodes were infrequent and occurred mostly at disease onset, which may limit their utility as specific trial endpoints. No safety or tolerability data were reported as no intervention was tested.

These results provide methodological considerations for researchers designing trials for ultra-rare diseases where recruitment is challenging. The study highlights the potential of registry data to establish stable historical controls and identify viable functional endpoints.

A study looked at the records of 462 patients with a rare condition called vanishing white matter. Because this disease is so rare, it can be hard to find enough people to participate in new medical trials. The researchers looked at how historical data from a registry could be used to help plan these trials.

The team found that the course of the disease remained consistent in the records from 1991 onwards. They also found that measuring a patient's ability to walk was a better way to track progress than just looking at survival rates. Additionally, they noted that while females appeared to have milder symptoms, this was actually linked to their age of onset rather than their sex.

This study is important because it focuses on how to design trials for very rare diseases. While the data shows that certain measurements are useful, the study does not test a specific new treatment or drug. It provides a roadmap for researchers to better understand and track disease progression using existing records.

What this means for you:

Registry data can help researchers design better clinical trials for rare conditions like vanishing white matter.

Common questions

What did the study find about tracking disease progress?

The study found that measuring a patient's ability to walk was a better way to track how the disease progresses compared to just looking at survival rates. They also found that scores for multi-domain function showed a clear link to how the disease progressed over time.

Did the study find differences between men and women?

The data showed that females had a later onset and milder symptoms. However, when researchers adjusted for the age at which the disease started, the difference between males and females disappeared. This suggests the timing of the disease is more important than sex.

Is this study testing a new treatment?

No, this study does not test a specific medication or treatment. Instead, it looks at how to use historical data from 462 patients to better design and organize future clinical trials for this rare condition.

Study Details

Study typeRct

Sample sizen = 462

EvidenceLevel 2

PublishedAug 2026

View Original Abstract ↓

Background: Therapy development in ultra-rare, progressive and fatal diseases like vanishing white matter (VWM) is hampered by very low patient numbers and ethical constraints regarding placebo-controlled studies. Under such conditions, standard randomized controlled trials may not be feasible. The use of historical control information could be part of a solution, but would require extra considerations regarding selection of patients and choice of endpoints. We used the VWM registry as a case study to outline key methodological considerations for informing trial design in ultra-rare disease. Methods: The study included 462 patients, available in the VWM registry. Prospective clinical data were collected since 2004 using VWM-specific questionnaire and Health Utility Index (HUI) assessments, while retrospective data from clinical charts were available from 1988 on. We evaluated methodological aspects relevant to trial design, including patient selection, drift in the disease course over time, endpoint selection, and clinically relevant stratification into subgroups. Results: Regarding patient selection, patients with comorbidities impacting disease course, and pre-symptomatic individuals without clinical onset were considered not suitable as historical controls. After excluding patients before 1991, we found no evidence of drift in the disease course from 1991 onwards. Regarding choice of endpoints, episodes of rapid decline were relatively infrequent and occurred mostly at disease onset, limiting their usefulness as trial endpoint. Multi-state modelling and clinical evaluation showed ambulation as preferable endpoint over survival. For longitudinal HUI multiscores, baseline imputation allowed modelling of early disease. The scores showed a distinct ordering, reflecting the association between multi-domain function and disease progression. Regarding stratification, the combination of data-driven analyses and clinical expertise informed revised age of onset groups. Females showed later onset and milder disease; adjustment for age of onset eliminated the effect of sex. Conclusion: This case study provides key considerations for evaluating registry data as historical control and demonstrates how these considerations can inform clinical trial design in ultra-rare diseases.

Registry data provides stable disease course and ambulation as preferred endpoint in Vanishing White MatterRegistry Data Helps Plan Trials for Vanishing White Matter

Common questions

Study Details

Acupuncture and related therapies improve Pittsburgh Sleep Quality Index scores in post-stroke insomnia

Acupuncture therapies show promise for insomnia after a stroke

Clinical research that matters. Delivered to your inbox.

Registry data provides stable disease course and ambulation as preferred endpoint in Vanishing White MatterRegistry Data Helps Plan Trials for Vanishing White Matter

Common questions

Study Details

Acupuncture and related therapies improve Pittsburgh Sleep Quality Index scores in post-stroke insomnia

Acupuncture therapies show promise for insomnia after a stroke

Clinical research that matters. Delivered to your inbox.

Related in Neurology

From Other Specialties